Medtronic announces the spin-off of its diabetes business to focus on high-margin growth drivers. CEO Geoff Martha emphasizes the move’s importance in delivering lasting value for shareholders, customers, and patients. The decision reflects Medtronic’s strategic shift towards intense focus on core competencies, with optimism for the future of the Diabetes business under Que’s leadership. This move underscores the company’s commitment to meeting the needs of individuals with diabetes globally, setting the stage for continued success and innovation.
Read more from medicaldialogues.in
